February 22, 2018 / 9:51 AM / 3 months ago

BRIEF-Novo Nordisk Says Successfully Completes First Trial For Oral Semaglutide

Feb 22 (Reuters) - NOVO NORDISK SAYS:

* SUCCESSFULLY COMPLETES THE FIRST PHASE 3A TRIAL, PIONEER 1, WITH ORAL SEMAGLUTIDE

* ‍TRIAL ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL PRINCIPLE BY DEMONSTRATING SIGNIFICANT AND SUPERIOR IMPROVEMENTS IN HBA (LONG-TERM BLOOD SUGAR) FOR ALL THREE DOSES OF ORAL SEMAGLUTIDE COMPARED TO PLACEBO​

* 14 MG DOSE OF ORAL SEMAGLUTIDE DEMONSTRATED SIGNIFICANT AND SUPERIOR WEIGHT LOSS VERSUS PLACEBO, WEIGHT LOSS WAS OBSERVED FOR 7 MG AND 3 MG DOSES BUT DID NOT REACH STATISTICAL SIGNIFICANCE​

* ‍WE ARE VERY ENCOURAGED BY RESULTS OF PIONEER 1 TRIAL, WHICH CONFIRM UNPRECEDENTED ORAL EFFICACY OF SEMAGLUTIDE THAT WAS REPORTED IN PHASE 2 CLINICAL TRIAL IN TYPE 2 DIABETES​

* ‍WE LOOK FORWARD TO PROVIDING DATA FROM REMAINING NINE PIONEER TRIALS THROUGHOUT THIS YEAR AND AN EXPECTED REGULATORY SUBMISSION IN 2019​ SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Jacob Gronholt-Pedersen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below